Payment overview · 2025
General Payments
$492.74
19 reported records · 8 companies
Healthcare provider profile · identity verified
Pushpinder Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YONKERS, NY · NPI 1326073552
Verified facts
What the public records show
CMS Open Payments records show Pushpinder Singh, M.D. received $492.74 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Entresto by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zubsolv by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.68 | 28.8% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.00 | 27.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.88 | 15.4% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $56.14 | 11.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.66 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.87 | 4.6% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $19.34 | 3.9% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $18.17 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.74 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $127.07 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.68 | 7 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $56.14 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.29 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $18.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 163 |
| Metoprolol Succinate | Metoprolol Succinate | 384 | 108 |
| Metformin Hcl | Metformin Hcl | 265 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 68 |
| Gabapentin | Gabapentin | 217 | 55 |
| Lisinopril | Lisinopril | 205 | 62 |
| Losartan Potassium | Losartan Potassium | 194 | 53 |
| Furosemide | Furosemide | 189 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 48 |
| Eliquis | Apixaban | 166 | 40 |
| Jardiance | Empagliflozin | 147 | 38 |
| Enalapril Maleate | Enalapril Maleate | 137 | 33 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 131 | 15 |
| Omeprazole | Omeprazole | 124 | 43 |
| Montelukast Sodium | Montelukast Sodium | 116 | 25 |
| Famotidine | Famotidine | 112 | 34 |
| Azithromycin | Azithromycin | 105 | 73 |
| Alendronate Sodium | Alendronate Sodium | 104 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 24 |
| Allopurinol | Allopurinol | 102 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 28 |
| Simvastatin | Simvastatin | 97 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 20 |
| Potassium Chloride | Potassium Chloride | 94 | 26 |
| Carvedilol | Carvedilol | 91 | 29 |
| Valsartan | Valsartan | 86 | 31 |
| Ozempic | Semaglutide | 84 | 17 |
| Alprazolam | Alprazolam | 76 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 67 | 16 |
| Farxiga | Dapagliflozin Propanediol | 65 | 16 |
| Spironolactone | Spironolactone | 65 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 11 |
| Trazodone Hcl | Trazodone Hcl | 62 | 16 |
| Irbesartan | Irbesartan | 61 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 16 |
| Meloxicam | Meloxicam | 59 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 18 |
| Mirtazapine | Mirtazapine | 56 | 12 |
| Nifedipine Er | Nifedipine | 56 | 18 |
| Clonazepam | Clonazepam | 55 | 12 |
| Entresto | Sacubitril/Valsartan | 54 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 16 |
| Levetiracetam | Levetiracetam | 50 | 12 |
| Meclizine Hcl | Meclizine Hcl | 50 | 16 |
| Torsemide | Torsemide | 50 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Prednisone | Prednisone | 44 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 15 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Glipizide | Glipizide | 42 | 19 |
| Atenolol | Atenolol | 41 | 12 |
| Glipizide Er | Glipizide | 41 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 15 |
| Naproxen | Naproxen | 38 | 13 |
| Ramipril | Ramipril | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 18 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 16 |
| Finasteride | Finasteride | 35 | 16 |
| Linzess | Linaclotide | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 18 |
| Baclofen | Baclofen | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Colchicine | Colchicine | 23 | 11 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.74 · 19 records | Amgen Inc. | AREXVY, LEQVIO, NEFFY, OTEZLA, QULIPTA, RECORLEV, REPATHA, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, Zubsolv | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error